Jay Venkatesan bought $1,048 of SER
director at Serina Therapeutics, Inc.. 589 shares at an average of $1.78, traded May 22, 2026, filed Jun 22, 2026.
Score components
- +15RoleDirector
- 0Trade size$1k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +8Price context68% below the 52-week high
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001413350-26-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 22, 2026 | POpen-market purchase Common Stock | +589 | $1.78 | $1,048 | 589 | Jun 22, 2026 |
| Jun 17, 2026 | CConversion Common Stockindirect: The Jay Venkatesan Legacy Trust | +224,152 | $2.25 | $504k | 231,705 | Jun 22, 2026 |
| Jun 17, 2026 | AGrant or award Stock Option (right to buy)derivative | +15,250 | $0.00 | $0 | 15,250 | Jun 22, 2026 |
| Jun 17, 2026 | CConversion Series A Convertible Preferred Stockderivativeindirect: The Jay Venkatesan Legacy Trust | -96,525 | $2.25 | $217k | 0 | Jun 22, 2026 |
Related signals
Other insiders at Serina Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | SERbuy Serina Therapeutics, Inc. | Stephen K. Brannan director | $2,030 1,000 shares | - | |
| 36Weak | SERbuy Serina Therapeutics, Inc. | Karen J Wilson director | $18k 10,100 shares | - | |
| 52Moderate | Serina Therapeutics, Inc. | Karen J Wilson director | $37k 20,000 shares | - | |
| 46Moderate | Serina Therapeutics, Inc. | Richard Peter Marshall director | $20k 12,183 shares | - | |
| 0Weak | Serina Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $19k 6,500 shares | -100% | |
| 10Weak | Serina Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $98k 39,000 shares | -100% | |
| 0Weak | Serina Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $20k 6,500 shares | -100% | |
| 0Weak | Serina Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $23k 6,500 shares | -100% | |
| 0Weak | Serina Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $7,375 2,500 shares | -100% | |
| 0Weak | Serina Therapeutics, Inc. | Randall Moreadith Chief Scientific Officer | $12k 4,000 shares | -200% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.